Aviv Marx
CEO & Co-founder
Claimed by owner SIS Shulov Innovative Science
Former names:
Novel Pharmaceutical Entities for Dermatology
SIS Shulov Innovative Science
About
Shulov Institute for Science (SIS) is an advanced clinical-stage biopharmaceutical company focusing on the development, manufacturing, and testing of novel pharmaceutical new chemical entities, based on natural compounds found in snake venom, towards clinical studies and commercialization.
The therapeutic targets for the current development are a wide range of dermatology indications including herpes (labialis, ocular, genital, and zoster), atopic dermatitis, psoriasis, and other skin disorders.
The leading compounds are short synthetic peptides (branded as ZEP-3 and ZEP-4), possessing unique biological activity and potent therapeutic use, including strong anti-viral, anti-inflammatory, and analgesic effects.
The company has completed an extensive chemistry, manufacturing, control package for the lead molecule API (ZEP-3) and is manufacturing under GMP in Israel and the United States.
SIS has completed a phase-II clinical study in herpes labialis (cold sores) with highly encouraging results in all end points, mainly time to healing, time to relief, and pain intensity.
The therapeutic targets for the current development are a wide range of dermatology indications including herpes (labialis, ocular, genital, and zoster), atopic dermatitis, psoriasis, and other skin disorders.
The leading compounds are short synthetic peptides (branded as ZEP-3 and ZEP-4), possessing unique biological activity and potent therapeutic use, including strong anti-viral, anti-inflammatory, and analgesic effects.
The company has completed an extensive chemistry, manufacturing, control package for the lead molecule API (ZEP-3) and is manufacturing under GMP in Israel and the United States.
SIS has completed a phase-II clinical study in herpes labialis (cold sores) with highly encouraging results in all end points, mainly time to healing, time to relief, and pain intensity.
Employees
Product stage
Primary Sector
Life Sciences & HealthTech
Products
ZEP-4, ZEP-3
Geographic markets
United States, Israel
Funding
Total Funding
Undisclosed
Last Funding
Undisclosed
Funding Stage
Total Rounds
0
Investors
0
The Team
(3)
AM
Ophir Shahaf
Founder
DNP
Dr. Naftali Primor
VP R&D
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Media gallery
(0)Locations
Israel
Prof. Hillel ve-Khanan Oppenheimer Street 10, Rehovot, Israel
Locations
Israel
Prof. Hillel ve-Khanan Oppenheimer Street 10, Rehovot, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,